SCHEMBL17501019

SCHEMBL17501019

CCOC(=O)N=S(C)(=O)c1ccc(Br)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
CDK1 P06493 4/20 0.48
CDK2 P24941 4/20 0.48
KDR P35968 4/20 0.48
NHERF1 O14745 1/20 0.47
KMT2A Q03164 3/20 0.42
F2 P00734 2/20 0.42
PRSS1 P07477 2/20 0.42
PRSS2 P07478 2/20 0.42
PRSS3 P35030 2/20 0.42
MEN1 O00255 1/20 0.42
S1PR4 O95977 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
S1PR1 P21453 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706509 0.87 POLB (0.54) POLBCDK1CDK2KDRKMT2A
SCHEMBL1706771 0.85 POLB (0.49) POLBCDK1CDK2KDRKMT2A
SCHEMBL14309236 0.84 POLB (0.55) POLBCDK1CDK2KDRKMT2A
SCHEMBL2817944 0.84 POLB (0.55) POLBCDK1CDK2KDRKMT2A
SCHEMBL17501270 0.82 POLB (0.44) POLBCDK1CDK2KDRKMT2A
SCHEMBL2821089 0.81 HPGD (0.62) POLBKMT2AF2PRSS1PRSS2
SCHEMBL17680266 0.79 NHERF1 (0.45) NHERF1KMT2AF2PRSS1PRSS2
SCHEMBL16394151 0.78 NPC1 (0.44) CDK1CDK2KDRF2PRSS1
SCHEMBL1706529 0.76 POLB (0.46) POLBKMT2AHPGDRAB9AHIF1A
SCHEMBL17501442 0.76 CA1 (0.43) POLBCDK1CDK2KDRF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-20 US disclosed
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-20 US disclosed
EP-3395818-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2021-09-22 EP disclosed
EP-3395818-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2021-09-22 EP disclosed
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-12-10 US disclosed
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-12-10 US disclosed
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-09-15 US disclosed
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-09-15 US disclosed
EP-3395818-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2018-10-31 EP disclosed
US-20180256591-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-09-13 US disclosed
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-03 US disclosed
EP-3177619-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2017-06-14 EP disclosed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 US disclosed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 US disclosed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 US disclosed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 US disclosed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 US disclosed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 US disclosed
WO-2016020320-A1 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-11 WO disclosed
WO-2016020320-A1 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180256591-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS POLB 40/4885CDK1 321/4885CDK2 63/4885
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS POLB 40/4885CDK1 321/4885CDK2 63/4885
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS POLB 40/4885CDK1 321/4885CDK2 63/4885
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS POLB 40/4885CDK1 321/4885CDK2 63/4885
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS POLB 40/4885CDK1 321/4885CDK2 63/4885
US-10772893-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS POLB 40/4885CDK1 321/4885CDK2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.